You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriamcinolone
Accession NumberDB00620  (APRD00422)
Typesmall molecule
Groupsapproved
Description

A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739)

Structure
Thumb
Synonyms
SynonymLanguageCode
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dioneNot AvailableNot Available
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dioneNot AvailableNot Available
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dioneNot AvailableNot Available
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dioneNot AvailableNot Available
9alpha-Fluoro-16alpha-hydroxyprednisoloneNot AvailableNot Available
9α-fluoro-16α-hydroxyprednisoloneNot AvailableNot Available
FluoxyprednisoloneNot AvailableNot Available
TiamcinolonumLatinINN
TriamcinolonaSpanishINN
TriamcinolonumNot AvailableINN
Salts
Name/CAS Structure Properties
Triamcinolone acetonide
Thumb Not applicable DBSALT000860
Triamcinolone diacetate
Thumb Not applicable DBSALT000859
Triamcinolone hexacetonide
Thumb Not applicable DBSALT000861
Brand names
NameCompany
AllerNazeNot Available
AristocortNot Available
AristospanNot Available
AzmacortNot Available
DelphicortNot Available
FlutexNot Available
KenacortNot Available
KenalogNot Available
KENALOG-10Not Available
KENALOG-40Not Available
NasacortNot Available
Omcilon-ANot Available
OracortNot Available
OraloneNot Available
Tri-NasalNot Available
TriacetNot Available
TriacortNot Available
TriadermNot Available
TrianexNot Available
TricortoneNot Available
TridermNot Available
TRIESENCENot Available
TriloneNot Available
TristojectNot Available
Brand mixtures
Brand NameIngredients
Aristoform R Crm 0.1%Clioquinol + Triamcinolone Acetonide
Derma-4 OntNeomycin Sulfate + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide
Kenacomb CreamGramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide
Kenacomb Mild CreamGramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide
Kenacomb Mild OintmentGramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide
Kenacomb OintmentGramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide
Kenacomb OntGramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide
Mecomb Crm 0.1%Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide
Oribiotic OintmentBacitracin + Lidocaine + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide
Panolog CreamNeomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide
Panolog OintmentNeomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide
Ratio-Triacomb Regular CreamGramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide
Solvaderm OintmentNeomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide
Theraderm CreamGramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide
Viaderm Kc CrmGramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide
Viaderm Kc OntGramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide
Categories
CAS number124-94-7
WeightAverage: 394.4339
Monoisotopic: 394.179166801
Chemical FormulaC21H27FO6
InChI KeyGFNANZIMVAIWHM-OBYCQNJPSA-N
InChI
InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
IUPAC Name
(1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-13,14,17-trihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Mass Specshow(9.24 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassLipids
ClassSteroids and Steroid Derivatives
SubclassGluco/mineralocorticoids, Progestogins and Derivatives
Direct parentGluco/mineralocorticoids, Progestogins and Derivatives
Alternative parentsHalogenated Steroids; Hydroxysteroids; Ketosteroids; Cyclohexanols; Tertiary Alcohols; Ketones; Cyclic Alcohols and Derivatives; Fluorohydrins; 1,2-Diols; Enolates; Primary Alcohols; Polyamines; Alkyl Fluorides; Aldehydes; Organofluorides
Substituents17-hydroxy-steroid; 11-hydroxy-steroid; 9-halo-steroid; 16-hydroxy-steroid; 3-keto-steroid; 20-keto-steroid; cyclohexanol; tertiary alcohol; cyclic alcohol; ketone; secondary alcohol; halohydrin; 1,2-diol; polyol; fluorohydrin; polyamine; primary alcohol; enolate; organofluoride; organohalogen; alcohol; carbonyl group; alkyl halide; alkyl fluoride; aldehyde
Classification descriptionThis compound belongs to the gluco/mineralocorticoids, progestogins and derivatives. These are steroids whose structure is based on an hydroxylated prostane moiety.
Pharmacology
IndicationFor the treatment of perennial and seasonal allergic rhinitis.
PharmacodynamicsTriamcinolone and its derivatives are synthetic glucocorticoids that are used for their antiinflammatory or immunosuppressive properties.
Mechanism of actionThe antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
AbsorptionRapid absorption following oral administration
Volume of distributionNot Available
Protein binding68%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life88 minutes
ClearanceNot Available
ToxicityLD50=>500mg/kg (in rats)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9823
Blood Brain Barrier + 0.9528
Caco-2 permeable + 0.7397
P-glycoprotein substrate Substrate 0.8204
P-glycoprotein inhibitor I Non-inhibitor 0.8759
P-glycoprotein inhibitor II Non-inhibitor 0.9725
Renal organic cation transporter Non-inhibitor 0.8178
CYP450 2C9 substrate Non-substrate 0.8858
CYP450 2D6 substrate Non-substrate 0.9006
CYP450 3A4 substrate Substrate 0.7049
CYP450 1A2 substrate Non-inhibitor 0.9144
CYP450 2C9 substrate Non-inhibitor 0.8939
CYP450 2D6 substrate Non-inhibitor 0.9231
CYP450 2C19 substrate Non-inhibitor 0.911
CYP450 3A4 substrate Non-inhibitor 0.9007
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.942
Ames test Non AMES toxic 0.8858
Carcinogenicity Non-carcinogens 0.9521
Biodegradation Not ready biodegradable 0.9952
Rat acute toxicity 2.3369 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9562
hERG inhibition (predictor II) Inhibitor 0.6125
Pharmacoeconomics
Manufacturers
  • Astellas pharma us inc
  • Bristol myers squibb co
  • Barr laboratories inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Abbott laboratories
  • Sanofi aventis us llc
  • Ivax pharmaceuticals inc
  • Apothecon inc div bristol myers squibb
  • Solvay pharmaceuticals
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Altana inc
  • Ambix laboratories div organics corp america
  • G and w laboratories inc
  • Morton grove pharmaceuticals inc
  • Perrigo new york inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Taro pharmaceuticals inc
  • Taro pharmaceuticals usa inc
  • Topiderm inc
  • Vintage pharmaceuticals llc
  • Del ray laboratories inc
  • Savage laboratories inc div altana inc
  • Parnell pharmaceuticals inc
  • Sandoz canada inc
  • Allergan inc
  • Alcon inc
  • Bristol myers squibb co pharmaceutical research institute
  • Wockhardt eu operations (swiss) ag
  • Carolina medical products co
  • Lyne laboratories inc
  • Lupin atlantis holding sa switzerland
  • Ranbaxy laboratories inc
  • Akorn inc
Packagers
Dosage forms
FormRouteStrength
Aerosol, meteredNasal
CreamTopical
LiquidIntramuscular
OintmentTopical
PasteDental
SprayNasal
SuspensionIntra-articular
SuspensionIntramuscular
SuspensionIntrasynovial
Prices
Unit descriptionCostUnit
Triesence 40 mg/ml vial148.8USDml
Kenalog Aerosol 63 gm Can118.99USDcan
Nasacort AQ 55 mcg/act Aerosol (Nasal Spray)118.74USDinhaler
Triamcinolone Acetonide 0.1% Paste 5 gm Tube71.7USDtube
Kenalog 0.5% Cream 20 gm Tube54.99USDtube
Kenalog 0.1% Lotion 60ml Bottle51.99USDbottle
Kenalog 0.025% Lotion 60ml Bottle46.99USDbottle
Triamcinolone Acetonide 0.025% Lotion 60ml Bottle40.99USDbottle
Triamcinolone diacetate powder26.01USDg
Triamcinolone powder20.29USDg
Kenalog 0.1% Cream 15 gm Tube18.99USDtube
Triamcinolone Acetonide 0.1% Ointment 80 gm Tube18.99USDtube
Triamcinolone Acetonide 0.5% Ointment 15 gm Tube14.99USDtube
Aristospan 20 mg/ml vial14.19USDml
Oralone 0.1% paste13.57USDg
Triamcinolone Acetonide 0.025% Cream 80 gm Tube12.99USDtube
Triamcinolone Acetonide 0.1% Cream 80 gm Tube12.99USDtube
Triamcinolone Acetonide 0.5% Cream 15 gm Tube12.99USDtube
Triamcinolone Acetonide 0.025% Cream 15 gm Tube11.99USDtube
Triamcinolone Acetonide 0.025% Ointment 80 gm Tube11.99USDtube
Triamcinolone Acetonide 0.1% Cream 15 gm Tube11.99USDtube
Triamcinolone Acetonide 0.1% Ointment 15 gm Tube11.99USDtube
Kenalog-40 40 mg/ml vial8.99USDml
Triamcinolone acet 40 mg/ml sus8.42USDml
Kenalog-40 40 mg/ml7.53USDml
Nasacort aq nasal spray6.99USDg
Triamcinolone 0.1% paste6.4USDg
Triamcinolone Acetonide 40 mg/ml6.29USDml
Triamcinolone Acetonide Usp 40 mg/ml5.76USDml
Aristospan 5 mg/ml vial3.54USDml
Kenalog-10 10 mg/ml3.24USDml
Triamcinolone Acetonide 10 mg/ml2.71USDml
Kenalog-10 10 mg/ml vial2.32USDml
Triamcinolone acet 10 mg/ml sus2.18USDml
Aristocort C 0.5 % Cream1.3USDg
Oracort 0.1 % Paste1.19USDg
Triderm 0.1% cream0.47USDg
Triamcinolone 0.5% cream0.22USDg
Aristocort R 0.1 % Cream0.15USDg
Aristocort R 0.1 % Ointment0.15USDg
Triamcinolone Acetonide 0.1% Cream0.07USDgm
Triaderm Regular 0.1 % Cream0.07USDg
Triamcinolone 0.025% cream0.06USDg
Triamcinolone Acetonide 0.1% Ointment0.05USDgm
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States63952942000-01-132020-01-13
United States59765731996-07-032016-07-03
Canada22689272003-09-232017-07-02
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point270 °CPhysProp
water solubility80 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.16HANSCH,C ET AL. (1995)
logS-3.69ADME Research, USCD
Predicted Properties
PropertyValueSource
water solubility8.47e-01 g/lALOGPS
logP0.84ALOGPS
logP0.24ChemAxon
logS-2.7ALOGPS
pKa (strongest acidic)11.75ChemAxon
pKa (strongest basic)-3.3ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count6ChemAxon
hydrogen donor count4ChemAxon
polar surface area115.06ChemAxon
rotatable bond count2ChemAxon
refractivity99.38ChemAxon
polarizability39.79ChemAxon
number of rings4ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterYesChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Abu Alam, “Triamcinolone formulations and methods for their preparation and use.” U.S. Patent US20040186084, issued September 23, 2004.

US20040186084
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD00385
PubChem Compound31307
PubChem Substance46507950
ChemSpider29046
Therapeutic Targets DatabaseDAP000417
PharmGKBPA451749
IUPHAR2870
Guide to Pharmacology2870
Drug Product Database2229540
RxListhttp://www.rxlist.com/cgi/generic/triamaer.htm
Drugs.comhttp://www.drugs.com/cdi/triamcinolone-spray.html
PDRhealthhttp://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/azm1044.shtml
WikipediaTriamcinolone
ATC CodesA01AC01D07AB09D07XB02H02AB08R01AD11R03BA06S01BA05C05AA12
AHFS Codes
  • 52:08.08
  • 84:06.00
  • 68:04.00
PDB EntriesNot Available
FDA labelshow(150 KB)
MSDSshow(72.6 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe corticosteroid, triamcinolone, alters the anticoagulant effect, acenocoumarol.
Acetylsalicylic acidThe corticosteroid, triamcinolone, may decrease the effect of the salicylate, acetylsalicylic acid.
AmbenoniumThe corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, ambenonium.
AmobarbitalThe barbiturate, amobarbital, may decrease the effect of the corticosteroid, triamcinolone.
AnisindioneThe corticosteroid, triamcinolone, alters the anticoagulant effect of anisindione.
AprobarbitalThe barbiturate, aprobarbital, may decrease the effect of the corticosteroid, triamcinolone.
Bismuth SubsalicylateThe corticosteroid, triamcinolone, may decrease the effect of the salicylate, bismuth subsalicylate.
ButabarbitalThe barbiturate, butabarbital, may decrease the effect of the corticosteroid, triamcinolone.
ButalbitalThe barbiturate, butalbital, may decrease the effect of the corticosteroid, triamcinolone.
ButethalThe barbiturate, butethal, may decrease the effect of the corticosteroid, triamcinolone.
DicoumarolThe corticosteroid, triamcinolone, alters the anticoagulant effect of dicumarol.
Dihydroquinidine barbiturateThe barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone.
EdrophoniumThe corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, edrophonium.
EthotoinThe enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, triamcinolone.
FosphenytoinThe enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, triamcinolone.
HeptabarbitalThe barbiturate, heptabarbital, may decrease the effect of the corticosteroid, triamcinolone.
HexobarbitalThe barbiturate, hexobarbital, may decrease the effect of the corticosteroid, triamcinolone.
Magnesium salicylateThe corticosteroid, triamcinolone, may decrease the effect of magnesium salicylate.
MephenytoinThe enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, triamcinolone.
MethohexitalThe barbiturate, methohexital, may decrease the effect of the corticosteroid, triamcinolone.
MethylphenobarbitalThe barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, triamcinolone.
MidodrineIncreased arterial pressure
NeostigmineThe corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, neostigmine.
PentobarbitalThe barbiturate, pentobarbital, may decrease the effect of the corticosteroid, triamcinolone.
PhenobarbitalThe barbiturate, phenobarbital, may decrease the effect of the corticosteroid, triamcinolone.
PhenytoinThe enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, triamcinolone.
PrimidoneThe barbiturate, primidone, may decrease the effect of the corticosteroid, triamcinolone.
PyridostigmineThe corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, pyridostigmine.
Quinidine barbiturateThe barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone.
RifampicinThe enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone.
Salicylate-sodiumThe corticosteroid, triamcinolone, may decrease the effect of the salicylate, salicylate-sodium.
SalsalateThe corticosteroid, triamcinolone, may decrease the effect of the salicylate, salsalate.
SecobarbitalThe barbiturate, secobarbital, may decrease the effect of the corticosteroid, triamcinolone.
TacrineTacrine and Triamcinolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
TalbutalThe barbiturate, talbutal, may decrease the effect of the corticosteroid, triamcinolone.
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Trisalicylate-cholineThe corticosteroid, triamcinolone, may decrease the effect of the salicylate, trisalicylate-choline.
VecuroniumVecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Triamcinolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
WarfarinThe corticosteroid, triamcinolone, alters the anticoagulant effect of warfarin.
Food InteractionsNot Available

Targets

1. Glucocorticoid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Glucocorticoid receptor P04150 Details

References:

  1. Nehme A, Lobenhofer EK, Stamer WD, Edelman JL: Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009 Sep 10;2:58. Pubmed
  2. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. Pubmed
  3. Shahin V, Ludwig Y, Schafer C, Nikova D, Oberleithner H: Glucocorticoids remodel nuclear envelope structure and permeability. J Cell Sci. 2005 Jul 1;118(Pt 13):2881-9. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Dort K, Padia S, Wispelwey B, Moore CC: Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther. 2009 Jun 8;6:10. doi: 10.1186/1742-6405-6-10. Pubmed
  2. Hagan JB, Erickson D, Singh RJ: Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. Pain Med. 2010 Jul;11(7):1132-5. doi: 10.1111/j.1526-4637.2010.00852.×. Epub 2010 Apr 29. Pubmed

2. Prostaglandin G/H synthase 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Prostaglandin G/H synthase 2 P35354 Details

References:

  1. Schaefer EC, Stewart AA, Durgam SS, Byron CR, Stewart MC: Effects of sodium hyaluronate and triamcinolone acetonide on glucosaminoglycan metabolism in equine articular chondrocytes treated with interleukin-1. Am J Vet Res. 2009 Dec;70(12):1494-501. doi: 10.2460/ajvr.70.12.1494. Pubmed

3. Cholinesterase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cholinesterase P06276 Details

References:

  1. Ehrich M, Jortner BS, Gross WB: Types of adrenocorticoids and their effect on organophosphorus-induced delayed neuropathy in chickens. Toxicol Appl Pharmacol. 1988 Feb;92(2):214-23. Pubmed

Carriers

1. Corticosteroid-binding globulin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Corticosteroid-binding globulin P08185 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Groyer A, Le Bouc Y, Joab I, Radanyi C, Renoir JM, Robel P, Baulieu EE: Chick oviduct glucocorticosteroid receptor. Specific binding of the synthetic steroid RU 486 and immunological studies with antibodies to chick oviduct progesterone receptor. Eur J Biochem. 1985 Jun 3;149(2):445-51. Pubmed
  4. Svec F, Harrison RW: Conditions affecting AtT-20 cell glucocorticoid uptake. Steroids. 1981 Feb;37(2):143-56. Pubmed
  5. Eisen HJ: An antiserum to the rat liver glucocorticoid receptor. Proc Natl Acad Sci U S A. 1980 Jul;77(7):3893-7. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11